ORIGINAL ARTICLE

Case-control study of medical history and idiopathic pulmonary fibrosis in Japan

Yoshihiro MIYAKE,[1] Satoshi SASAKI,[2] Tetsuji YOKOYAMA,[3] Kingo CHIDA,[4] Arata AZUMA,[5] Takafumi SUDA,[4] Shoji KUDOH,[5] Naomasa SAKAMOTO,[6] Kazushi OKAMOTO,[7] Gen KOBASHI,[8] Masakazu WASHIO,[9] Yutaka INABA,[10] Heizo TANAKA[2] AND THE JAPAN IDIOPATHIC PULMONARY FIBROSIS STUDY GROUP*

[1]*Department of Public Health, Fukuoka University School of Medicine, Fukuoka,* [2]*National Institute of Health and Nutrition, Tokyo,* [3]*Department of Technology Assessment and Biostatistics, National Institute of Public Health, Wako,* [4]*Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu,* [5]*Fourth Department of Internal Medicine, Nippon Medical School, Tokyo,* [6]*Department of Hygiene, Hyogo College of Medicine, Nishinomiya,* [7]*Department of Public Health, Aichi Prefectural College of Nursing and Health, Nagoya,* [8]*Department of Health for Senior Citizens, Hokkaido University Graduate School of Medicine, Sapporo,* [9]*Department of Public Health, Sapporo Medical University School of Medicine, Sapporo and* [10]*Department of Epidemiology, Juntendo University School of Medicine, Tokyo, Japan*

Case-control study of medical history and idiopathic pulmonary fibrosis in Japan
MIYAKE Y, SASAKI S, YOKOYAMA T, CHIDA K, AZUMA A, SUDA T, KUDOH S, SAKAMOTO N, OKAMOTO K, KOBASHI G, WASHIO M, INABA Y, TANAKA H, THE JAPAN IDIOPATHIC PULMONARY FIBROSIS STUDY GROUP. *Respirology* 2005; **10**: 504–509

Objectives: A few epidemiological studies have indicated that a patient's past medical history may contribute to the risk of developing idiopathic pulmonary fibrosis (IPF). A relationship between a history of selected disorders and the risk of IPF was assessed in a multicentre hospital-based case-control study in Japan.

Methodology: Included in the study were 104 patients of IPF, aged 40 years or over, who had been diagnosed within the previous 2 years, in accordance with the most recent criteria. Control subjects, aged 40 years or over, consisted of 56 hospitalized patients diagnosed as having acute bacterial pneumonia and four outpatients with the common cold. Adjustment was made for age, gender, region, pack-years of smoking, employment status, occupational exposure and BMI.

Results: Medical histories of hypertension, hyperlipidaemia, coronary heart disease, diabetes mellitus, hepatitis C virus infection, tuberculosis, asthma, atopic dermatitis and allergic rhinitis were not statistically significantly associated with the risk of IPF, although cases were more likely to have suffered from allergic rhinitis and less likely to have been asthmatics than control subjects. Having a child with a history of allergic rhinitis, but not of asthma or atopic dermatitis, was significantly related to an increased risk of IPF.

Conclusions: These findings suggest that a genetic predisposition to allergic rhinitis may be associated with an increased risk of IPF.

Key words: case-control studies, hay fever, Japan, pulmonary fibrosis.

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a progressive and usually fatal lung disease characterized by fibroblast proliferation and extracellular matrix remodelling, leading to irreversible distortion of the lung architecture.[1] Patients with IPF are often between 40 and 70 years of age and approximately two-thirds are over the age of 60 years at the time of presentation.[2] Although the aetiology is unknown, factors relating to aging may be implicated in the pathogenesis of IPF. For example, a few epidemiological studies have indicated that a patient's medical history may contribute to the risk of developing IPF. A recent case-control study in Japan demonstrated that diabetes mellitus was significantly associated with a fourfold increased risk of IPF.[3] A case-control study in the UK suggested that atopy may be an important determinant of susceptibility to IPF.[4] An increased prevalence of antibodies to hepatitis C virus was observed in both Japanese and Italian patients with IPF,[5,6] while Irving *et al.* failed to confirm these findings in a British series of patients with IPF.[7]

To confirm these reported findings, we examined the relationship between a history of selected disorders and the risk of IPF, based on data from a multicentre hospital-based case-control study in Japan.

METHODS

Subjects

Eligible cases were patients aged 40 years or over, who had been diagnosed within the previous 2 years and who were identified among the 21 collaborating hospitals and their 29 affiliated hospitals during the period from 1 June to 30 November 2001. The diagnosis of IPF by the collaborating respiratory disease specialists was based on clinical history, clinical examination and high-resolution CT (HRCT) of the chest. Results of video-assisted thoracoscopic lung biopsy, transbronchial lung biopsy and/or BAL, corresponding to the international consensus statement on IPF of the American Thoracic Society and European Respiratory Society,[8] were also used when available, either alone or in combination, to assist diagnosis. All patients had basal fine crackles on auscultation and predominantly peripheral, subpleural, bibasal fine reticular shadows and/or honeycombing, occasionally with traction bronchiectasis and bronchiolectasis on HRCT. There was no evidence of either coexisting collagen-vascular disease or a history of known occupational exposure to agents that might produce a clinical picture similar to that of IPF in any of the patients. The physicians-in-charge asked eligible patients to participate in this study, and 104 patients were cooperative in answering the questionnaires, while three patients refused.

Control subjects were aged 40 years or over, had no prior respiratory diseases and were prospectively selected from individuals who received treatment at the respiratory ward of the recruiting hospitals, dur-

ing the same time period as the cases. Fifty-six hospitalized patients, diagnosed as having acute bacterial pneumonia, and four outpatients with common cold served as controls by answering the same questionnaires as the cases. Controls were not, individually or in larger groups, matched with cases. Patients with acute infectious or common diseases are unlikely to receive treatment at a specialized medical institution. Fourteen of the 21 collaborating hospitals were university hospitals with doctors who exclusively treated patients with serious illnesses. Thus, 95 of the 104 cases were recruited from the 21 collaborating hospitals, while 34 of the 60 controls were selected from the 29 hospitals that were affiliated with the collaborating hospitals.

The study subjects were originally restricted to males, but included in the analysis were 10 female cases and five female controls, whose treatment was provided at six of the collaborating hospitals and one affiliated hospital. A total of 104 cases and 60 control subjects who gave their fully informed consent remained in the present study.

Questionnaires

The physicians handed a set of two self-administered questionnaires to the cases and the controls. The subjects filled out the questionnaires and mailed them to the data management centre. A telephone interview was conducted by a trained research technician in order to complete missing or illogical data.

One of the self-administered questionnaires was used to ascertain age, gender, weight, height, smoking habits, type of job held for the longest period of time, occupational exposure, personal medical history and a history of asthma, atopic dermatitis and allergic rhinitis (including cedar pollinosis) in the subject's children. Hypertension, hyperlipidaemia, coronary heart disease, diabetes mellitus, tuberculosis, asthma, atopic dermatitis and allergic rhinitis (including cedar pollinosis) were defined as being present when subjects had received medication, or in the case of diabetes mellitus, if they were receiving dietary therapy. Hepatitis C virus was considered to be present if the subject had been diagnosed by a physician as being infected with hepatitis C virus or being its carrier. A child's history of asthma, atopic dermatitis and allergic rhinitis (including cedar pollinosis) was considered to be confirmed if one or more of the study subject's children had been treated for these conditions with medications at any time since birth. Occupational exposure was defined as being present if the subject had been exposed to any of eight specific occupational agents (metal, wood, asbestos, coal, stone and sand, solvents, pesticide or chalk) for 10 or more hours per week for more than 1 year. BMI was calculated by dividing self-reported body weight (kg) by height (m) squared.

The other self-administered questionnaire was a validated diet history questionnaire that was used to assess dietary habits over a period of 1 month.[9,10] Data obtained from this diet history questionnaire were not used in the present study.

Table 1 Clinical features of idiopathic pulmonary fibrosis cases

Lung function	Mean	SD	Minimum	Median	Maximum
Arterial O_2 pressure (mmHg)	79.6	11.4	50.0	80.6	102.0
Vital capacity (% predicted)	77.4	22.0	19.8	77.6	128.0

Arterial O_2 pressure: 8-values missing. Vital capacity: 5-values missing.

Statistical analysis

Multiple logistic regression analysis was used to estimate adjusted odds ratios (OR) and their 95% confidence intervals (CI) for IPF relative to selected medical histories. Covariates included in the multivariate models were age, gender, region, pack-years of smoking, employment status, occupational exposure and BMI, which was used as a continuous variable. Age was classified into four categories (<50, 50–59, 60–69 and ≥70 years); region into five (Kanto-Koshinetsu, Tokai, Kinki, Chugoku-Shikoku and Kyushu); employment status into two (high employment status as represented by professionals, technical workers, managers and officials, and other); and pack-years of smoking into five (never, 0 < –19.9, 20.0–39.9, 40.0–59.9 and ≥60.0). In two cases and one control, data on smoking were missing and they were regarded as never having smoked. All computations were performed using the SAS software package version 8.2 (SAS Institute Inc., Cary, NC, USA).

RESULTS

Dyspnoea on exertion was present at enrollment in 84 of the 104 cases (80.8%). The median (90% central range) arterial O_2 pressure was 80.2 mmHg (57.2–98.0 mmHg) and the median vital capacity in the cases, expressed as per cent predicted value, was 78.0% (42.1–113.5%) (Table 1). About 90% of both cases and controls were male (Table 2). In comparison with controls, cases were older, fewer were resident in Chugoku-Shikoku and had never smoked, and more cases had high employment status, occupational exposure and were overweight.

In Table 3, adjusted OR for associations between selected medical histories and IPF are presented. After controlling for gender and age, hypertension, hyperlipidaemia, coronary heart disease, diabetes mellitus and hepatitis C virus infection were not significantly associated with the risk of IPF. Further adjustment for region, pack-years of smoking, employment status, occupational exposure and BMI did not materially modify these results. Tuberculosis tended to be related to a decreased risk of IPF after adjusting for gender and age, but the relationship was almost completely attenuated in the multivariate model. There was a tendency for an inverse association between asthma and the risk of IPF: the multivariate OR was 0.22 (95% CI 0.04–1.09). Atopic dermatitis did not appear to be related to IPF. Allergic rhinitis was associated with a twofold increased risk

Table 2 Characteristics of the study population

Variable	No. (%) or mean (SD) Cases ($n = 104$)	Controls ($n = 60$)	P-value
Gender (% male)	94 (90.4)	55 (91.7)	0.78
Age (% years)			0.10
<50	3 (2.9)	2 (3.3)	
50–59	16 (15.4)	19 (31.7)	
60–69	56 (53.9)	25 (41.7)	
≥70	29 (27.9)	14 (23.3)	
Region (%)			0.21
Kanto-Koshinetsu	57 (54.8)	27 (45.0)	
Tokai	12 (11.5)	10 (16.7)	
Kinki	14 (13.5)	5 (8.3)	
Chugoku-Shikoku	4 (3.9)	7 (11.7)	
Kyushu	17 (16.4)	11 (18.3)	
Pack-years of smoking (%)			0.26
Never	20 (19.2)	15 (25.0)	
0 < –19.9	10 (9.6)	11 (18.3)	
20.0–39.9	30 (28.9)	10 (16.7)	
40.0–59.9	29 (27.9)	15 (25.0)	
≥60.0	15 (14.4)	9 (15.0)	
High employment status (%)[†]	18 (17.3)	8 (13.3)	0.50
Occupational exposure (%)[‡]	33 (31.7)	5 (8.3)	0.0006
BMI (kg/m²)	23.3 (3.1)	21.9 (3.0)	0.005

[†]Subjects considered to have a high employment status were those who were professionals, technical workers, managers or officials for the longest period within their working years.

[‡]Exposure to metal, wood, asbestos, coal, stone and sand, solvents, pesticide, or chalk for 10 or more hours per week for more than 1 years.

of IPF, although the 95% CI included the null hypothesis value.

We further examined the relationship between an allergic history in at least one child and the risk of IPF. The multivariate OR for having a child with a history of asthma was 1.82 (95% CI 0.54–7.04), of atopic dermatitis, 0.91 (95% CI 0.30–2.77) and of allergic rhinitis, 2.49 (95% CI 1.01–6.54).

DISCUSSION

The present study demonstrated that having a child with a history of allergic rhinitis, but not asthma

Table 3 Odds ratios for idiopathic pulmonary fibrosis in relation to selected items from personal and child's medical history

Variable	No. (%) Cases	No. (%) Controls	Gender and age adjusted Odds ratio	Gender and age adjusted 95% confidence interval	Multivariate adjusted[†] Odds ratio	Multivariate adjusted[†] 95% confidence interval
Personal history						
Hypertension	28 (26.9)	15 (25.0)	1.00	0.48–2.14	0.56	0.23–1.35
Hyperlipidaemia	10 (9.6)	4 (6.7)	1.63	0.50–6.37	1.35	0.34–6.39
Coronary disease	10 (9.6)	3 (5.0)	1.58	0.45–7.39	1.31	0.32–6.76
Diabetes mellitus	13 (12.5)	7 (11.7)	0.95	0.36–2.74	1.43	0.46–4.76
Hepatitis C virus	7 (6.7)	4 (6.7)	0.85	0.22–3.60	0.80	0.15–4.27
Tuberculosis	7 (6.7)	9 (15.0)	0.35	0.12–1.03	0.58	0.17–1.94
Asthma	4 (3.9)	6 (10.0)	0.39	0.09–1.48	0.22	0.04–1.09
Atopic dermatitis	2 (1.9)	1 (1.7)	1.31	0.12–29.99	1.76	0.12–46.06
Allergic rhinitis	12 (11.5)	4 (6.7)	1.96	0.62–7.58	2.00	0.53–9.19
Child's history						
Asthma	12 (11.5)	5 (8.3)	1.56	0.53–5.33	1.82	0.54–7.04
Atopic dermatitis	9 (8.7)	9 (15.0)	0.56	0.20–1.56	0.91	0.30–2.77
Allergic rhinitis	30 (28.9)	11 (18.3)	1.94	0.89–4.49	2.49	1.01–6.54

[†]Adjusted for age, gender, region, pack-years of smoking, employment status, occupational exposure and BMI.

or atopic dermatitis, was significantly related to an increased risk of IPF. Hypertension, hyperlipidaemia, coronary heart disease, diabetes mellitus, hepatitis C virus infection, tuberculosis, asthma, atopic dermatitis and allergic rhinitis were not significantly associated with the risk of IPF after adjustment for potential confounders, although cases were more likely to have suffered from allergic rhinitis and were less likely to have been asthmatic than control subjects.

The prevalence of allergic disorders has been increasing in Japan.[11] In particular, the prevalence of allergic rhinitis was likely to be underestimated in the present study because the disorder was defined as being present when subjects had been under medical treatment. The prevalence of seasonal rhinitis, which was defined as having symptoms from February to May, was 28.8% among Japanese male railway employees.[12] The consequence of such a hypothetical misclassification would have been to introduce a bias toward the null hypothesis. A previously cited study also demonstrated an inverse association between advancing age and the prevalence of allergic rhinitis.[12] A significant positive relationship between having a child with a history of allergic rhinitis and the risk of IPF, as identified in this study, may support the causality. Genetic predisposition to allergic rhinitis or the joint effect of the genetic background and environmental factors such as exposure to metal dust and smoking, may be associated with the development of IPF.

Our results are in contradiction to a recent Japanese case-control study showing a significant positive association between diabetes mellitus and the risk of IPF.[3] In the present investigation, the definition of diabetes mellitus was crude because only individuals who had been receiving dietary or drug treatment were considered to be diabetics and results of fasting blood sugar or glycosylated haemoglobin testing were not available. Thus, latent or untreated diabetics were

missed, and such misclassification may have masked a true positive association. Matsuse *et al.* found that all lung tissue samples obtained from seven necropsy cases with IPF showed strong advanced glycation end-product expression on alveolar macrophages.[13] Advanced glycation end-product modification may be involved in the pathogenesis of IPF. An animal experiment demonstrated that the morphological grade of fibrosis in mice with streptozotocin-induced diabetes was more severe than that in mice treated with bleomycin alone.[14] Lack of a positive relationship between hypertension or hyperlipidaemia and the risk of IPF in this study is in agreement with a previously cited study in Japan.[3] However, caution is needed in interpreting our findings because hypertension and hyperlipidaemia were defined by the use of drugs. The reported OR associated with such diseases may have been underestimated.

With regard to hepatitis C virus infection, our findings are in agreement with a UK observation,[7] but at variance with previous Japanese and Italian studies that showed an increased prevalence of hepatitis C virus infection in patients with IPF.[5,6] The discrepancy between our results and those from the previous Japanese study might be ascribed to the high false-positive rates from the first generation ELISA tests used in the previous Japanese study.[5] Eight of 60 patients with IPF were, however, hepatitis C virus-RNA positive in the previously cited Italian study.[6] The prevalence of hepatitis C virus positivity is high in Japan as well as in Italy. Egan *et al.* suggested that it is most likely that the relationship between hepatitis C virus infection and IPF is spurious and reflects the background rate of hepatitis C virus infection.[15]

The present study had methodological advantages. Cases were selected according to the most recent diagnostic criteria and extensive information on potential confounding factors was incorporated. Weaknesses of this study should be borne in mind. Although selection bias in the choice of cases was

not likely to have occurred because of the high response rate (only three eligible patients refused), control subjects may not have been representative of the general population from which the cases arose, because almost all controls were hospitalized patients with acute bacterial pneumonia. In fact, the prevalences of hypertension and diabetes mellitus were relatively high in the present study. In a population-based case-control study of acute myocardial infarction in Fukuoka, Japan, the proportions of persons with hypertension and diabetes mellitus, using the same definitions as in this study, were 13% and 10%, respectively, among 260 male controls less than 65 years of age, and 21% and 8%, respectively, in 212 male controls aged 65 years or over.[16] The corresponding figures for hypertension and diabetes mellitus in the present study were 27% and 10%, respectively, in 30 male controls less than 65 years old, and 28% and 16%, respectively, in 25 male controls aged 65 years or over. Our control subjects may have been likely to have had histories of medical conditions such as hypertension and diabetes mellitus. Such a hypothesis would give rise to an underestimation of our results. If acute bacterial pneumonia shared risk factors with IPF, the reported OR would have been underestimated. Eligible control subjects with acute bacterial pneumonia were not likely to be recruited during the summer months because of seasonal variation in this disease. The ratio of controls to cases was below 1:1 and our investigation did not have substantial statistical power. In the present study, the percentages of atopic dermatitis sufferers among cases and controls were 1.9% and 1.7%, respectively. A case-control study is not suitable for studying rare exposures.

Our findings suggest that a genetic predisposition to allergic rhinitis may be associated with an increased risk of IPF. Further investigations with more precise and detailed exposure measurements are required to confirm whether allergic rhinitis is an independent risk factor for IPF, and to clarify our results that showed lack of a relationship between diabetes mellitus and IPF, which was in disagreement with previous reports.

ACKNOWLEDGEMENT

REFERENCES

1 Selman M, King TE Jr, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. *Ann. Intern. Med.* 2001; **134**: 136–51.

2 American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. *Am. J. Respir. Crit. Care Med.* 2000; **161**: 646–64.

3 Enomoto T, Usuki J, Azuma A, Nakagawa T, Kudoh S. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. *Chest* 2003; **123**: 2007–11.

4 Marsh P, Johnston I, Britton J. Atopy as a risk factor for cryptogenic fibrosing alveolitis. *Respir. Med.* 1994; **88**: 369–71.

5 Ueda T, Ohta K, Suzuki N *et al.* Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. *Am. Rev. Respir. Dis.* 1992; **146**: 266–8.

6 Meliconi R, Andreone P, Fasano L *et al.* Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. *Thorax* 1996; **51**: 315–17.

7 Irving WL, Day S, Johnston IDA. Idiopathic pulmonary fibrosis and hepatitis C virus infection. *Am. Rev. Respir. Dis.* 1993; **148**: 1683–4.

8 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Am. J. Respir. Crit. Care Med.* 2002; **165**: 277–304.

9 Sasaki S, Yanagibori R, Amano K. Self-administered diet history questionnaire developed for health education: a relative validation of the test-version by comparison with 3-day diet record in women. *J. Epidemiol.* 1998; **8**: 203–15.

10 Sasaki S, Ushio F, Amano K *et al.* Serum biomarker-based validation of a self-administered diet history questionnaire for Japanese subjects. *J. Nutr. Sci. Vitaminol.* 2000; **46**: 285–96.

11 Yura A, Shimizu T. Trends in the prevalence of atopic dermatitis in school children: longitudinal study in Osaka Prefecture, Japan, from 1985 to 1997. *Br. J. Dermatol.* 2001; **145**: 966–73.

12 Sakurai Y, Nakamura K, Teruya K *et al.* Prevalence and risk factors of allergic rhinitis and cedar pollinosis among Japanese men. *Prev. Med.* 1998; **27**: 617–22.

13 Matsuse T, Ohga E, Teramoto S *et al.* Immunohistochemical localisation of advanced glycation end products in pulmonary fibrosis. *J. Clin. Pathol.* 1998; **51**: 515–19.

14 Usuki J, Enomoto T, Azuma A, Matsuda K, Aoyama A, Kudoh S. Influence of hyperglycemia to the severity of pulmonary fibrosis. *Chest* 2001; **120** (Suppl. 1): 71S.

15 Egan JJ, Woodcock AA, Stewart JP. Viruses and idiopathic pulmonary fibrosis. *Eur. Respir. J.* 1997; **10**: 1433–7.

16 Miyake Y, Fukuoka Heart Study Group. Risk factors for non-fatal acute myocardial infarction in middle-aged and older Japanese. *Jpn. Circ. J.* 2000; **64**: 103–9.

APPENDIX 1 OTHER MEMBERS OF THE JAPAN IDIOPATHIC PULMONARY FIBROSIS STUDY GROUP

Eiichi Suzuki (Internal Medicine II, Niigata University Medical Hospital); Michihiko Haraguchi (Department of Respiratory Medicine, Niigata City General Hospital); Katsuya Fujimori (Department of Internal Medicine, Niigata Prefectural Shibata Hospital); Yasuharu Saito (Department of Respiratory Medicine, National Nishi-Niigata Central Hospital); Shoji Ohno, Yukihiko Sugiyama (Division of Pulmonary Medicine, Department of Medicine, Jichi Medical School); Kazuo Kawaguchi (Department of Medicine, Oyama Municipal Hospital); Yasuo Sugama (Department of Medicine, Utsunomiya Social Health Insurance Hospital); Koichiro Nakata, Tatsuo Nakatani (Division of Respiratory Diseases, Toranomon Hospital); Kiyoshi Takenaka (First Department of Internal Medicine, Hakujikai Memorial Hospital); Naoko Tojo, Yasuyuki Yoshizawa (The Integrated Pulmonary Medicine, Tokyo Medical and Dental University); Ken Ohta (Department of Medicine, Teikyo University School of Medicine); Atsushi Nagai (First Department of Medicine, Tokyo Women's Medical University); Kazuyuki Nishimura (Department of Medicine, Saiseikai Kurihashi Hospital); Haruko Matsumiya (Department of Medicine, Aoyama Hospital); Yutaka Izawa (Department of Medicine, National Hospital Tokyo Disaster Medical Center); Yasuhiro Setoguchi (Department of Respiratory Medicine, Juntendo University School of Medicine); Rokuro Matsuoka (Department of Pulmonary Medicine, Showa General Hospital); Minoru Kanazawa (Saitama Cardiovascular and Respiratory Center); Makoto Yonemaru (Department of Internal Medicine, National Higashisaitama Hospital); Hiroaki Matsubara (Internal Medicine, Fussa Hospital); Takeshi Terashima (Department of Internal Medicine, Tokyo Dental College Ichikawa General Hospital); Yutaka Nakano (Department of Internal Medicine, Hamamatsu Rosai Hospital); Hitoshi Gemma (Department of Internal Medicine, Fukuroi Municipal Hospital); Shiro Imokawa (Department of Internal Medicine, Hamamatsu Social Insurance Hospital); Hiroshi Hayakawa (Department of Internal Medicine,

National Tenryu Hospital); Kazumasa Yasuda (Department of Respiratory Medicine, Iwata City Hospital); Yasuhiro Kondoh, Hiroyuki Taniguchi (Department of Respiratory and Allergic Medicine, Tosei General Hospital); Yoshio Taguchi (Department of Respiratory Medicine, Tenri Hospital); Hiromi Tomioka (Department of Respiratory Medicine, Nishi-Kobe Medical Center); Ryoichi Amitani (Department of Respiratory Medicine, Osaka Red Cross Hospital); Machiko Arita (Department of Respiratory Medicine, Kurashiki Central Hospital); Sonoko Nagai (Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University); Yoshikazu Inoue, Mitsunori Sakatani (Department of Diffuse Lung Diseases and Respiratory Failure, Clinical Research Center, National Kinki-Chuo Hospital for Chest Diseases); Nobuyuki Katakami (Division of Pulmonary Medicine, Kobe City General Hospital); Takeshi Isobe, Nobuoki Kohno (Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University); Masao Kuwabara (Department of Pulmonary Medicine and Rheumatology, Hiroshima Prefectural Hospital); Takehiko Hiramoto (Department of Respiratory Medicine, National Medical Center of Kure); Toshihiko Kuraoka (Federation of National Public Service Personnel Mutual Aid Association, Yoshijima Hospital); Hironobu Hamada, Akihito Yokoyama (Second Department of Internal Medicine, Ehime University School of Medicine); Masahiro Abe (Department of Respiratory Medicine, Ehime National Hospital); Masahiro Shiode (Department of Respiratory Medicine, Uwajima City Hospital); Kazuya Ichikado (First Department of Internal Medicine, Kumamoto University School of Medicine); Eishi Miyazaki, Toshiyuki Sawabe (Division of Pulmonary Diseases, Department of Immunology and Allergy, Oita Medical University); Shigeru Kohno, Hiroshi Mukae (Second Department of Internal Medicine, Nagasaki University School of Medicine); Osamu Sakito (Internal Medicine, Omura Municipal Hospital); Koh Abe (Third Department of Internal Medicine, Miyazaki Medical College); Yuji Ishimatsu (Internal Medicine, Sasebo City General Hospital).

Behçet病の最近の疫学像の動向

A recent trend of epidemiological feature of Behçet's disease

黒沢美智子(写真)　**稲葉　裕**

Michiko KUROSAWA and Yutaka INABA

順天堂大学医学部衛生学教室

◎Behçet 病の全国疫学調査は 1972 年にはじめて実施された. 以後 5〜7 年間に 1 回の頻度で行われているが, 今回の第 5 回目の調査は前回(1991)から 11 年目を経て実施された. 本調査は患者数を推計する一次調査と臨床疫学像を明らかにする二次調査からなり, 厚生労働省難治性克服研究事業特定疾患の疫学に関する研究班, ベーチェット病に関する調査研究班が共同で実施した. その結果, 2002 年 1 年間に Behçet 病で受診した患者数は 15,000 人(95%信頼区間 14,000〜16,000)と推計された. 1972 年以降, 患者数推計値, 受療患者数ともに増加していたが, 今回はじめて減少に転じた. 臨床疫学像としては 30 年間で完全型 Behçet の割合が段階的に減少しており, とくに男性での減少が顕著であった. 重症度分類では女性より男性, とくに若年で発症した男性に重症・中等度者が多かった.

Key word : Behçet病, 全国疫学調査, 患者数推計, 臨床疫学像

厚労省難治性克服研究事業特定疾患の疫学に関する研究班(主任研究者:稲葉　裕)とベーチェット病に関する調査研究班(主任研究者:金子史男)は, 2002 年 1 年間に Behçet 病で受療した患者を対象に全国疫学調査を実施した. 難治性克服研究事業対象疾患の全国疫学調査は患者数を推計する一次調査と臨床疫学像を明らかにする二次調査からなり, 上記疫学班と該当疾患の臨床班との共同研究として実施されているものである. Behçet 病の全国疫学調査は 1972 年にはじめて実施され, 以後 5〜7 年間に 1 回の頻度で行われているが, 今回第 5 回目の調査は前回(1991)から 11 年目を経て実施された. 本稿では今回の全国疫学調査結果とこれまでに実施された調査結果を比較し, Behçet 病の最近の疫学像の動向について述べる.

2003年に実施した全国疫学調査の概要

疫学班で作成された全国疫学調査マニュアル[1]に基づき, 一次調査の対象を 2002 年 1 月 1 日〜12 月 31 日の 1 年間の受療患者, 調査対象科を内科(含膠原病科, リウマチ科), 眼科, 皮膚科とし,

特別階層を 20 床以上の眼科, 皮膚科病院として全国の病院から病床規模別に層化無作為抽出された計 2,914 科(表 1)を対象医療施設とし, 2003 年 1 月に患者数推計のための一次調査票を郵送した.

一次調査で Behçet 病患者ありと回答のあった施設を二次調査対象とした. 一次調査で得られた報告患者数をもとに二次調査結果より不適格率, 重複率を考慮して患者数の推計を行った. 二次調査の実施計画は, 主任研究者所属施設の倫理審査委員会の承認を得, 2003 年 11 月に調査を開始した.

一次調査結果(患者数推計)と30年間の患者数の推移

病床規模別の対象数, 抽出率, 抽出数, 各疾患の報告患者数を表 1 に示す. 一次調査の回収数は 1,674 診療科(回収率 57.4%), 報告患者数は 7,652 例であった. 二次調査票より対象期間外や診断基準を満たさない不適格率は 4.6%, 重複率は調査票が匿名であるため求められないが, 同施設内の明らかな重複(2.5%)を考慮して 1 年間の受療患者数を 15,000 人(95%信頼区間 14,000〜16,000), 男

表 1 Behçet病全国疫学調査一次調査の対象数，抽出率，報告患者数

対象科	規模	対象数	抽出率	抽出数	返送数	合計
皮膚科	20〜99 床	897	6.2	56	29	6
	100〜199 床	597	9.9	59	25	6
	200〜299 床	359	19.8	71	36	26
	300〜399 床	330	39.7	131	78	88
	400〜499 床	176	80.1	141	77	208
	500 床以上	229	100.0	229	151	604
	特別階層	2	100.0	2	2	1
	大学病院	115	100.0	115	89	601
小計		2,705		804	487	1,540
内科	20〜99 床	3,280	5.0	164	101	22
	100〜199 床	1,542	9.8	151	70	24
	200〜299 床	622	19.9	124	54	73
	300〜399 床	406	39.9	162	83	141
	400〜499 床	205	80.0	164	79	168
	500 床以上	243	100.0	243	119	539
	特別階層	0		0	0	0
	大学病院	235	100.0	235	177	1,676
小計		6,533		1,243	683	2,643
眼科	20〜99 床	443	12.6	56	28	6
	100〜199 床	538	10.0	54	30	16
	200〜299 床	414	20.0	83	41	46
	300〜399 床	346	39.9	138	82	171
	400〜499 床	180	80.0	144	91	263
	500 床以上	231	100.0	231	123	583
	特別階層	38	100.0	38	27	137
	大学病院	123	100.0	123	82	2,247
小計		2,313		867	504	3,469
合計		11,551		2,914	1,674	7,652

表 2 過去に実施した全国調査推計患者数と医療費受給者数の推移

調査年	全国調査	受給者数
1972	8,500	—
1979	11,500	4,766
1984	13,000	7,921
1991	18,400	12,987
2002	15,000(14,000〜16,000)	16,834

性 7,000 人(95％信頼区間 6,500〜7,500)，女性 8,000 人(95％信頼区間 7,500〜8,500)と推計した．

　過去に実施した全国調査推計患者数と医療費受給者数の推移を表 2[2-4)に示す．1991 年の推計患者数は不適格率を考慮していないが 18,400 人で，今回の推計患者数はそれより数千人少なかった．推計患者数減少の理由は不明であるが，医療費受給者数も 2001 年をピークに減少している．今回の全国調査二次調査結果などから Behçet 病患者は軽

症者の割合が増加していることが考えられ，それが今回の推計値に影響した可能性もある．

二次調査(臨床疫学像)結果と過去の調査結果との比較

　回収された二次調査票は不適格例，重複例，性別不明を除いた 1,884 例(一次調査報告患者数の 24.6％)について分析した．性別は男性 906 例 (48.1％)，女性 978 例(51.9％)，男性は 30〜50 歳

図1 最近1年間の受療状況——1972年と2002年
　の比較

■：おもに入院　■：おもに通院　□：入院と通院　□：その他・不明

図2 性別にみた重症度割合

■：重症　■：中等度　図：軽症　□：症状なし

図3 性別発症年齢別重症度割合

■：重症　■：中等度　図：軽症　□：症状なし

図4 病型（完全型と不全型）別割合の推移（男性）

図：不全型　■：完全型

図5 病型（完全型と不全型）別割合の推移（女性）

図：不全型　■：完全型

代が多く，女性は50〜60歳代が多かった．1997年度のBehçet病医療受給者[3]の年齢分布と比べると，本調査対象者は若年男性の報告がやや多かった．二次調査票の性比は0.93で，一次調査の性比0.88，2002年度のBehçet病医療受給者[5]の性比0.74と比べるとやや男性の報告が多かった．平均年齢は男性47.8歳，女性51.3歳で，1972年調査結果[2]より約10歳高くなっていた．発症年齢のピークは，男性30〜35歳，女性35〜45歳，平均

発症年齢は男性35.0歳，女性38.1歳で，1972年調査結果[2]と比べると男女とも4歳高くなっていた．

　本調査結果で家族歴を有するのは1.9％で，1972年の1.8％[6]とほぼ同じ結果であった．最近1年間の受療状況（図1）は，30年前と比べると大きく変化している．1972年には"おもに入院"が約10％，"入院と通院"が約17％いたが，2002年の調査では"おもに入院"は0.7％に減少し，"入院と通院"も8％に減少しており，通院（86.5％）の割合が多くなっていた．

　今回調査項目に加わった重症度（図2）は，重症・中等度の割合が男性49.7％，女性23.1％と男性での割合が高く（$p<0.001$），重症度には性差が顕著に認められた．また，性別発症年齢別（図3）にみると重症・中等度者の割合は40歳未満の男性で高く，半数以上を占めていた．

　病型については疑い例，分類不能例を除く完全型，不全型のみの割合の推移を性別に図4，5に示す．1972年の男性の完全型Behçetの割合は50.8％と半数を超えていたが，その後段階的に減少[7,8]しており，2002年には29.9％まで減少してい

表 3 主症状別性別有病割合の推移

症状		調査年			
		1972	1984	1991	2002
口腔内アフタ	男性	97.9%	—	98.0%	87.6%
	女性	98.8%	—	98.0%	92.1%
皮膚症状	男性	89.8%	—	87.0%	70.1%
	女性	90.4%	—	87.0%	78.3%
眼症状	男性	86.3%	66.4%	71.4%	70.0%
	女性	67.8%	35.0%	35.7%	45.3%
外陰部潰瘍	男性	76.8%	47.1%	32.2%	43.8%
	女性	83.8%	77.8%	71.5%	64.6%

た(図 4). 同じく 1972 年の女性の完全型の割合は男性より少ない 38.7%であったが, それ以降徐々に減少し, 2002 年には 27.8%に減少していた(図 5). 完全型 Behçet の減少はとくに男性に顕著であった.

これまでに出現した主症状(口腔内アフタ, 皮膚症状, 眼症状, 外陰部潰瘍)の割合の推移[6,9]を性別に表 3 に示す. 1972 年から 30 年間に口腔内アフタは男性が約 10%減少, 女性もやや減少していた. 同じく皮膚症状は男性が約 20%, 女性は 10%強減少していた. 眼症状は性差が大きいが, 1972 年から 1984 年にかけて男性は 20%, 女性は 30%以上減少し, その後はほとんど変化が認められない. 外陰部潰瘍は 30 年間で女性は約 20%減少しているが, 男性は 1972 年から 1984 年にかけて約 30%減少し有病割合は 47.1%となった. さらに 1991 年に有病割合は 32%まで減少したが, 今回の調査では 43.8%まで上昇していた. 今回の調査結果のみであるが, 虹彩毛様体炎, 網膜ぶどう膜炎有の割合は若年発症者で高く, 皮下の血栓性静脈炎有は女性の高齢発症者に高いという特徴があった. HLA-B51 陽性率は 71.4%(1972), 58.1%(1984), 54.9%(1991), 48.7%(2002)と推移していたが, HLA-B51 は毎回二次調査対象者の約 30%しか測定されておらず, 測定者は重症者や悪化している人に多いなどの偏りがあるため, 陽性率の変化についての解釈は慎重にする必要がある.

今回, 過去 30 年間に実施された全国調査結果を比較し, Behçet 病の患者数の推移や臨床像の変化を示し最近の疫学像を示した. 今後は平成 14 年 (2002)度より全都道府県から厚生労働省にオンラインで集積される臨床調査個人票の分析[10]によって臨床像やその推移をより詳細に把握することが期待される.

文献

1) 大野良之・他(編):難病の患者数と臨床疫学像把握のための全国疫学調査マニュアル. 厚生省特定疾患難病の疫学調査研究班, 1994.
2) 大野良之・他(総編集):難病の最新情報―疫学から臨床・ケアまで. 南山堂, 2000, pp.106-110.
3) 永井正規・他(編):特定疾患治療研究医療受給者調査報告書(1997 年度分)その 1 基本集計. 厚生科学研究特定疾患対策研究事業特定疾患の疫学に関する研究班, 2000.
4) Kurosawa, M. et al.:Nationwide epidemiological survey of Behçet diseases in 2003 in Japan. *Clin. Exp. Rheumatol.*, **22**(4)(Suppl. 34):S84, A1, 2004.
5) 太田晶子・他:2002 年度地域保健・老人保健事業報告による全国特定疾患医療受給者の実態把握. 厚生労働科学研究難治性疾患克服研究事業特定疾患の疫学に関する研究平成 16 年度総括・分担研究報告書. 2005.
6) 清水 保・他(編):ベーチェット病患者全国疫学調査成績. 厚生省特定疾患ベーチェット病調査研究班, 1974.
7) 中江公裕:ベーチェット病疫学ハンドブック―重要疾患の疫学と予防(日本疫学会編). 南山堂, 1998, pp.256-259.
8) Inaba, Y. et al.:Epidemiologic and clinical characteristics of Behçet disease in Japan:Results from nationwide survey in 2003. *Clin. Exp. Rheumatol.*, **22** (4)(Suppl. 34):S84, A2, 2004.
9) 中江公裕:最近のベーチェット病の疫学. 日本醫事新報, **3717**:124-126, 1995.
10) 永井正規・他(編):電子入力された臨床調査個人票に基づく特定疾患治療研究医療受給者調査報告書. 厚生労働科学研究難治性疾患克服研究事業特定疾患の疫学に関する研究班, 2005.

ORIGINAL ARTICLE

Changes in the incidence of amyotrophic lateral sclerosis in Wakayama, Japan

TAMEKO KIHIRA[1], SOHEI YOSHIDA[2], MASAYA HIRONISHI[1], HIDETO MIWA[1], KAZUSI OKAMATO[3] & TOMOYOSHI KONDO[1]

[1]*Department of Neurology, Wakayama Medical University, Wakayama City,* [2]*Kansai College of Oriental Medicine, Osaka, and* [3]*Department of Public Health, Aichi Prefectural College of Nursing and Health, Nagoya, Japan*

Abstract

In the 1960s, the incidence of amyotrophic lateral sclerosis (ALS) in the Kozagawa and Koza areas in Wakayama prefecture was much higher than that in other areas of the world. However, between 1980 and 1993, a gradual decrease in the incidence of the disease in these areas was reported. To ascertain whether the decreased incidence has persisted, we conducted a retrospective epidemiological study, and determined the average annual incidence of ALS in Wakayama prefecture from 1998 to 2002. The number of ALS cases encountered during the period was 134 (male 79, female 55). The crude average annual incidence in Wakayama prefecture in total was 2.50 (male 3.08, female 1.99) per 100,000. In the Kozagawa and Koza areas in Wakayama prefecture, where the senility rate rapidly increased in recent years, the average annual incidence of ALS in the present research was 10.56 (male 14.14, female 7.66). When the crude rate was standardized for both age and sex to the Japanese population in 1990, the expected value was 5.24 (male 7.34, female 3.18), which was lower than that of our previous survey. The prevalence in Wakayama prefecture at 31 December 2002 was 11.31 (male 14.40, female 8.53). In Kozagawa and Koza areas, the crude prevalence was 52.81 (male 70.70, female 38.28). These results indicated that the incidence of ALS in Wakayama prefecture, especially for females, steadily decreased compared to that in previous reports. However, a high incidence of ALS persisted among males in Wakayama prefecture, especially in the Kozagawa and Koza areas. Some environmental factors and gender specificity may be related to the decreased incidence of ALS in focus areas.

Key words: *Focus ALS, Kii-ALS, environmental factor, incidence*

Introduction

Amyotrophic lateral sclerosis (ALS) is a devastating disease affecting the upper and lower motor neurons, causes of which are unknown. Retrospective studies reported that the incidence of ALS in the world varied from 0.6 to 2.6 per 100,000 of the population and the prevalence from 1.6 to 8.5 per 100,000 of the population. In the southern part of the Kii Peninsula of Japan as well as on the island of Guam, the incidence and prevalence rates of ALS in the 1960s were 100 to 150 times higher than those of other countries in the world (1,2). However, over 30 years' follow-up studies in Kii Peninsula foci (Kozagawa in Wakayama prefecture and Hobara in Mie prefecture) demonstrated a marked decline in the incidence of ALS. A previous study during the period 1989 to 1993 in Wakayama prefecture also indicated that the incidence rate of the disease

decreased steadily except in the Kozagawa area, where the crude incidence rate was reported to be 9.54 (two ALS cases within five years: 4193 base population) (3). The environmental or socioeconomic changes over 30 years probably played some roles in the decline in ALS occurrence in Kii Peninsula (4,5). This study documented the incidence and prevalence of ALS in Wakayama prefecture of the Kii Peninsula during five recent years and investigated whether a continuous decline in the occurrence of the disease persisted.

Methods

Area of investigation

The Kii Peninsula is located in the central southern part of the Japanese mainland, facing the western Pacific Ocean with a rugged coast and steeply

mountainous regions about 1000 m above sea level (Kumano mountains) (Figure 1). Wakayama prefecture covers the southwest side of the Kii Peninsula, and includes seven cities, 36 towns, seven villages and eight public health districts with a resident population of 1,069,912 (male 506,882, female 563,030, in the 2000 census). Demographic data of Wakayama prefecture are shown in Table I. In the Kozagawa and Koza areas, immigrant influx and emigration rate to other areas have been very low. The proportion of people over 65 years old in Wakayama prefecture increased 3 times in the past 40 years. In Kozagawa and Koza areas, the senility rate rapidly increased in recent years. With regard to the proportion of the employed population, there was no difference between Wakayama prefecture in total and the focus areas (Table I). From south to north, the province includes three different geographic and economic regions (mountainous, level, and urban areas). The area of investigation was divided into these three regions (from region A to region C as shown in Figure 1). Region A is in the most northern section of the prefecture and is an economically developing region with a flat and mildly mountainous area; region B includes the prefecture's capital and urban area; region C is predominantly rural area with a rugged coast and steep mountains. Region C covers a geographically large part of the Wakayama prefecture, and includes the high incident area of ALS (Kozagawa and Koza areas) which is subdivided as region C (f). Each region has several main hospitals and public health centers.

Case collection and ascertainment

First, two mail survey questionnaires at 589 clinics and hospitals where ALS would be potentially diagnosed were conducted from 1 January 1998 to 31 December 2002. Physicians in these medical facilities were asked to register all patients diagnosed with ALS during that period according to the modified El Escorial diagnostic criteria (6). Second, the Wakayama Prefecture's List of Patients with Intractable Disease (WPLPID, as certified by the Ministry of Health and Welfare of Japan) were used for ascertainment. All cases of progressive bulbar palsy (PBP) and primary lateral sclerosis (PLS) were included among the incident


Figure 1. Wakayama prefecture, covering level and mountainous areas of 4725 km^2, is situated in the middle of the Japan mainland between 33°25' and 34°23'N and 136°0' and 134°59'E. Subdivisions into regions in Wakayama prefecture are shown as A, B, C and C(f). Sources: Statistics Bureau, MIC and Statistical Handbook of Japan, Statistics Bureau, MIC.

Table I. Demographic data in Wakayama Prefecture.

	Population in the 2000 census			Emigrations		Immigrations		Proportion of old people			Occupations in 1995		
	Total(A)	Male	Female	Number of emigrants	To other Prefectures (B)(B/A%)	Number of immigrants	From other Prefectures (C)(C/A%)	1960 (%)	1990/1995* (%)	2000 (%)	Agriculture, forestry and fishing (%)	Secondary industries (%)	Tertiary industries (%)
Wakayama Prefecture	1,069,912	506,882	563,030	37,345	21,204 (1.98)	33,454	17,213 (1.61)	7.3	15.3/18.10*	21.2	11.7	28.2	59.5
Kozagawa area	3,726	1,662	2,064	91	50 (1.34)	98	47 (1.26)	un	37.08*	42.62	13.1	28.2	58.8
Koza area	5,742	2,581	3,161	176	69 (1.20)	190	84 (1.46)	un	28.25*	32.97	12.7	23.3	64

Sourse: Tokei nennkan 2003 from Wakayama Prefecture   un: unknown

cases for this study, but familial progressive muscular atrophy was excluded. All cases were diagnosed by neurologists (registered with Societas Neurologica Japonica: Japanese Association of Neurology) at the main hospitals in Wakayama prefecture (Wakayama Laborer's Hospital, Japan Red Cross Hospital, Wakayama Medical University, and other public hospitals) and were verified for this survey by the authors. ALS patients were registered using the initials of their name, gender, date of birth, and residence area as well as their clinical data. To maintain the confidentiality of each personal record, we used the patient's initials and municipality of residence rather than full names and detailed addresses. The protocol of this study was approved by the Wakayama Medical Ethics Association.

Since the crude incidence and mortality rate generally increase with age, it is difficult to compare those rates between two populations with different age distribution simply, e.g., an area with predominantly young population and that with predominantly elderly population. When comparing those rates in this study, we used age-adjusted rates that can be compared without the influence of age distribution.

Age-adjusted rates were calculated by direct methods using the population in 2000 and in 1990 in Japan as the standard.

Statistical analysis

The difference in proportions was assessed with the χ^2 test, and that in incidence and mortality rates was analysed by Z score. The differences were assessed with two-sided tests, with an alpha level of 0.05; 95% confidence intervals (95% CI) for incidence and mortality were calculated assuming a Poisson distribution.

Results

The questionnaire response rate was 58% on the first occasion, and 99% on the second. There were 215 Japanese cases registered as having MND in Wakayama prefecture. Of these, 134 (male 79, female 55) cases were newly diagnosed as possible, probable, or definite ALS during the five-year period between 1998 and 2002 (Table II). Of the 215 cases, 121 patients with ALS were living in Wakayama prefecture on 31 December 2002.

Clinical features

The clinical features of the 134 ALS cases are listed in Table III. The male/female ratio was 1.43:1, different from that of the general population of Wakayama prefecture (direct method) ($\chi^2=7.21$, df=1,

Table II. Number of cases during the 5-year study period.

Year	Number of patients			Number of deaths		
	Total	Male	Female	Total	Male	Female
2002	20	8	12	2	1	1
2001	35	20	15	7	4	3
2000	19	16	3	9	8	1
1999	33	22	11	15	10	5
1998	27	13	14	13	5	8
Annual average	26.8	15.8	11	9.2	5.6	3.6
Total	134	79	55	46	28	18

Table III. Clinical characteristics of patients (1998~2002).

| Total		134	%
Male/Female		79/55	1.43/1
Family history (+)		5	3.73
Clinical signs at onset	Bulbar	27	20.15
	Bulbar and upper limb	8	5.97
	Upper limb disturbance	41	30.60
	Lower limb disturbance	24	17.91
	Upper and lower limb disturbance	16	11.94
	Respiratory disturbance	6	4.48
	Primary lateral sclerosis	2	1.49
	Not defined	10	7.46
ALS associated with dementia		8	5.97

Figure 2. Ages at onset of 134 patients with ALS in Wakayama prefecture, 1998–2002.

$p<0.0073$). Five cases (3.73%) had familial ALS based on detailed family history. The most frequent clinical sign at onset was upper limb disturbance, and the second was bulbar sign. The mean age at onset was 65.7 ± 9.4 years (mean $\pm$ SD, range 40–85 years), 65.7 ± 9.6 for males (range 40–85 years), and 65.8 ± 9.3 for females (range 41–82) (Figure 2).

Incidence

Incidence rates based on the newly diagnosed 134 ALS cases are shown in Table IV. The average annual crude incidence in Wakayama prefecture was 2.50 (male 3.08, female 1.99) per 100,000 population. The incidence rates of ALS in Wakayama prefecture after adjustment for both age and gender to the 2000 or 1990 Japanese population (direct method) were 2.23 and 1.84 respectively (95% CI 1.33–3.21), 2.27 and 2.19 for male, and 1.79 and 1.51 for female. There was no significant difference in the age- and gender-adjusted incidence rates between males and females ($\chi^2=0.2$, df=1, $p<$NS). Regarding the age- and gender-adjusted incidence rates according to the three regions of Wakayama prefecture (regions A, B, and C), a low tendency of the incidence rate for females in the urban area (region B) of 1.43, when age-adjusted to the 2000 Japanese females was indicated, but there was

no significant difference ($\chi^2=0.43$, df=3, $p<$NS). The highest age- and gender-adjusted incidence was for males in Kozagawa and Koza areas (region C (f)) (9.53 age-adjusted to the 2000 Japanese population) with significant difference ($\chi^2=3.77$, df=1, $p=0.05$). There were five ALS cases diagnosed during the survey period at Kozagawa and Koza areas (base population 4243 for males and 5225 for females). The average annual incidence for ALS was consistently higher for males than for females in all regions. There were no cases diagnosed before 39 years of age, and the incidence generally increased with advancing age. Regarding the incidence per 5-year age class, two peaks were found for males at 11.66 per 100,000 population between 60 and 64 years, and 14.41 per 100,000 population between 80 and 84 years. For females, a peak was found at 7.73 per 100,000 population between 70 and 74 years (Figure 3). The incidence at 80 to 84 years of age was significantly higher in males than in females ($\chi^2=5.56$, df=1, $p<0.01$).

Prevalence

There were 121 patients (male 72, female 49) with ALS residing in the community on the prevalence assessment date of 31 December 2002. The crude prevalence in Wakayama prefecture on the prevalence day was 11.31 (14.40 per 100,000 population for male, 8.53 per 100,000 population for female). Geographically, the prevalence rates were almost equivalent in these 3 blocks except for region C(f), where the rate was highest at 52.81 per 100,000 population (70.70 for males and 38.28 for females (Table V).

Mortality

The mortality rate was calculated based on deaths due to ALS each year. The crude annual mortality rate was 0.86 per 100,000 population (males 1.10, females 0.64). The age-specific mortality rate adjusted to the 1990 Japanese population was 0.58 per 100,000 population (males 0.72, females 0.44) (Table VI). The disease duration of all registered

Table IV. Number and average annual incidence per 100,000 population for ALS in Wakayama Prefecture, 1998–2002.

	Males			Females			Total			
District#	Number of cases	Crude rate	Age adjusted rate*(**)	Number of cases	Crude rate	Age adjusted rate*(**)	Number of cases	Crude rate	Age adjusted rate*(**)	95% CI
A	17	3.21	3.26 (2.66)	12	2.08	2.06 (1.66)	29	2.62	2.65 (2.16)	0.50–4.79
B	32	2.95	2.63 (2.02)	20	1.65	1.43 (1.21)	52	2.26	2.05 (1.66)	0.74–3.35
C	30	3.27	2.72 (2.28)	23	2.14	1.76 (1.52)	53	3.35	2.21 (1.87)	0.74–3.69
C(f)	3	14.14	9.53## (7.34)	2	7.66	4.16 (3.18)	5	10.56	6.57 (5.24)	
Total	79	3.08	2.72 (2.19)	55	1.99	1.79 (1.51)	134	2.50	2.23 (1.84)	1.33–3.12

* Rate adjusted to the Japanese 2000 population. ** Rate adjusted to the Japanese 1990 population.
#: District as shown in Fig. 1.
##: $\chi^2=3.77$, df=1, P=0.05.

Figure 3. Incidence per 100,000 population per 5-year age class in Wakayama prefecture between 1998 and 2002.

Table V. Prevalence of ALS per 100,000 population at 31 December 2002.

	No. of cases			Prevalence			
	Male	Female	Total	Male	Female	Total	95% CI
Region A	12	11	23	11.34	9.55	10.40	6.15–14.65
Region B	31	19	50	14.27	7.85	10.89	7.87–13.91
Region C	30	18	48	16.33	8.75	12.32	8.83–15.81
Region C(f)	3	2	5	70.70	38.28	52.81	6.53–99.08
Wakayama Prefecture	73	48	121	14.40	8.53	11.31	9.30–13.33

Table VI. The annual average mortality rate per 100,000 population for ALS in Wakayama Prefecture, 1998–2002.

	Male			Females			Total			
Region#	No. of deaths	Crude rate	Age adjusted rate*	No. of deaths	Crude rate	Age adjusted rate*	No. of cases	Crude rate	Age adjusted rate*	95% CI
A	6	1.13	0.82	4	0.69	0.55	10	0.90	0.68	
B	10	0.92	0.64	5	0.41	0.29	15	0.65	0.47	
C	12	1.31	0.76	9	0.87	0.61	21	1.08	0.69	
Total	28	1.10	0.72	18	0.64	0.44	46	0.86	0.58	0.13–1.04

* Rate adjusted to the Japanese 1990 population.
#:Region as shown in Fig. 1.

ALS patients was 59.5 ± 44.0 (months, mean $\pm$ SD) in region A, 67.98 ± 64.43 in region B, and 80.33 ± 78.95 in region C, showing no significant difference. The disease duration of ALS cases diagnosed between 1998 and 2002 was 23.9 ± 13.25 (months, mean $\pm$ SD) for region A, 22.07 ± 13.57 for region B, and 22.14 ± 14.83 for region C, showing no significant difference.

Discussion

The average annual incidence of ALS in Wakayama prefecture during the period 1998 to 2002 was 2.50 per 100,000 population (male 3.08, female 1.99), and 1.84 (male 2.19, female 1.51) adjusted to the 1990 Japanese population. The present results indicated a steady decline of the incidence rate compared to that of the 1960s survey in Wakayama prefecture, especially for females. Compared to those of the survey during 1989 to 1993, which reported 1.25 for total, 1.86 for male, and 0.61 for female, the present results showed a mild increase. They probably reflect the differences between survey methods, more careful case ascertainment, improvement of diagnostic skills, increased frequency of patients consulting hospitals, prevailing care

information of the disease, and aging of the population. Regarding the geographic regions, there was no significant difference in the incidence rate among the areas except for that of males in the focus area. In the Kozagawa and Koza areas, the crude annual incidence rate of ALS for males was significantly higher than that of Wakayama prefecture in general. The age-adjusted annual incidence in these focus areas was 5.24 (males 7.34, females 3.18) per 100,000 population adjusted to the 1990 Japanese population, showing a decline compared to the incidence in the survey during 1989 to 1993 (3). In other areas of the world, the crude annual incidence was reported 1.0 to 1.5 per 100,000 population in Japan (10, 11), 0.66 to 0.69 in Hokkaido, Japan (12), 1.7 in Minnesota between1925 and 1998 (13), 0.6 to 2.6 in eight countries including the USA, northern Sweden, Finland, and Canada (14). These reported rates were similar to the present results for females in the total Wakayama prefecture. However, the incidence for males in Wakayama prefecture in all geographic regions including urban, level, and mountainous areas especially in Kozagawa and Koza areas, was higher than those in these reports.

The male/female ratio of ALS cases in the present study was significantly higher compared to that of the general population of the Wakayama prefecture, and the age-class incidence of ALS between 80 and 84 years of age was significantly higher in males than in females. Sample error caused by possibilities of inclusion of the same subject in both indices, 2 periods, and 2 populations on the results might occur. In this study, we used $Z = (r_s - r_L)\sqrt{n}/(r_L - r_L^2)$ *(r_s*: rates for smaller population; r_L: rates for larger population; *n*: total sample for smaller population) for analysis of significance of difference, assuming the presence of a sample error. However, the difference was statistically significant, indicating that even if there was a sample error, its influence may have been sufficiently small. Many published studies have reported a male predominance with a range between 1.2:1 and 2.0:1, but an exception is studies from middle-Finland (7) and from Modena, Italy (8). The reason for male predominance remains unknown. A possible explanation is that males are more likely to sustain physical injury, a suspected risk factor for the occurrence of MND (9), or the presence of a protective gene for the clinical manifestation of MND on the X chromosome.

Historically, a markedly higher frequency of MND was first recognized in a small village Mitogawa in Kozagawa town of Kii Peninsula in 1965 (2). The house-to-house survey of the entire population of 1307 people in Mitogawa village had documented four confirmed and six suspected cases. Over the following eight years, further surveys throughout the Kozagawa area had found a high

annual incidence of 14.4 and a crude prevalence rate of 96.9 per 100,000 population (six MND cases in a population of 6191). Over the following 15 years between 1965 and 1980 in the Kozagawa area and total Wakayama prefecture, a steady decrease in the incidence was reported (5). The decline in incidence was partly due to emigration of patients with ALS from the focus area, misdiagnosis, or concealment of the disease because the patient felt stigmatized. After 1980, newly diagnosed patients were found, and a subsequent survey from 1989 to 1993 indicated that the incident rate in Kozagawa area was 9.54. In the present study, the incidence rate in the focus area was 14.14 per 100,000 population for males (7.34 when age-adjusted to the 1990 population). Although the number of elderly people increased compared to that in 1968, the recent incidence rates were similar to those of the initial survey (4). It indicated that the high incidence of ALS still remained in the southern part of Wakayama prefecture, especially in males.

On the Guam islands, the incidence of ALS was higher than anywhere else in the world in the 1960s. From the late 1960s to the early 1980s, a decline in incidence on the islands was recognized. The recent survey also showed the incidence falling below 3 per 100,000 population for males and for females by 1999 (15). While it showed a decline in Wakayama prefecture as a whole similar to that of Guam, the average annual incidence for males in the Kozagawa and Koza areas remained higher than those in other areas of the world. Wakayama prefecture is a rather isolated region, especially the southern part of the prefecture, and the migration of ALS patients during the survey period was limited except for transfers within the same prefecture (one ALS patient transferred to another prefecture). In the Hobara area, where the markedly high incidence of ALS and Parkinsonian-dementia complex (PDC) was recently reported (16), a familial trait was demonstrated, as in the Guam islands, although genetic contribution to the pathogenesis remains unclear. There were five familial ALS cases in Wakayama prefecture (3.8%, one case in the Koza area), which was similar to the numbers reported elsewhere in the world. Considering the lack of familial trait and the decline in incidence in other areas of Wakayama prefecture, the high incidence of ALS in the Kozagawa and Koza areas may be due more to environmental than genetic factors. It may also be ascribed to some socioeconomic factors and a possible unknown gender-specific risk factor.

The crude prevalence of ALS in Wakayama prefecture was 11.31 on 31 December 2002 in this study. It was 52.81 (males 70.70, females 38.28) in the Kozagawa and Koza areas, which was higher than the prevalence in other reports. The crude prevalence was 4.7 per 100,000 population in

Ireland (17), and 4.02 in Modena, Italy (8). It was reported to be 73.9 per 100,000 population in the Koza area in 1963(2), and 152.7 per 100,000 population in the Hobara area (4). The prevalence throughout Wakayama prefecture in the 1960s had been reported to be as high as 20.0 to 33.3 per 100,000 population (2). Compared to the rates in these previous reports, the present prevalence in the prefecture decreased; however, a markedly high rate in the focus areas still persisted. The age-adjusted mortality rate in Wakayama prefecture in the present survey was 0.58 per 100,000 population (males 0.72, females 0.44), which was lower compared to 0.93 reported between 1990 and 1994 in Wakayama prefecture (18) and to other reports from countries including Italy (8), Scotland, Canada (19), and the United States (20). The high prevalence and low mortality rate in the present survey may partly reflect an improvement in community care systems and care skills including mechanical ventilators, NIPPV and PEG. Thirteen cases (10.7%) with ALS in Wakayama prefecture, however, have survived without the use of mechanical ventilators for over 10 years. A long clinical duration was observed to be one of the characteristics of Kii ALS, and was similar to that of Guam ALS (21).

The average age at onset of ALS in the present study was 64.7 years old, and the age specific incidence for males per 100,000 population showed two peaks at 60 to 64, and 80 to 84 years old. The average age at onset in the present survey increased compared to that in previous Japanese reports, 54.2 years in Japan in 1982 (18), 58.2 in Hokkaido between 1980 and 1989 (12). The mean age at onset in the present survey was similar to that reported in other countries, 65 years in California between 1970 and 1986 (22), 63 years in Minnesota between 1925 and 1998 (13). In Israel, the age-specific incidence and the mean age of onset increased from 1959 to 1974 (23). The increase in age at onset may be partially explained by an increased elderly population with a high risk for ALS. Changes in living habits (e.g., dietary patterns) and environmental factors may have also played some role in the increased age at onset.

Conclusions

The present results indicated that the incidence of ALS in Wakayama prefecture decreased compared to that reported in 1968, and for females the incidence of ALS in Wakayama prefecture was similar to those reported in other parts of the world. However, a high incidence of ALS persisted among males in the Kozagawa and Koza areas of Wakayama prefecture. Some environmental factors and gender specificity may be related to the development of ALS in Wakayama prefecture.

References

1. Kusui K. Epidemiological study on amyotrophic lateral sclesoris (ALS) and other neighboring motor neuron diseases in Kii Peninsula. Psychiat Neurol Jpn. 1962;65:86–99.
2. Kimura K. Studies of amyotrophic lateral sclerosis in the Kozagawa district in the Kii Peninsula. Jpn Wakayama Med J. 1965;9:177–92.
3. Yoshida S, Uebayashi Y, Kihira T, Kohmoto J, Wakayama I, Taguchi S, Yase Y. Epidemiology of motor neuron disease in the Kii Peninsula of Japan, 1989–1993: active or disappearing focus? J Neurol Sci. 1998;155:146–55.
4. Yase Y, Matsumoto N, Yoshimasu F, Handa Y, Kumamoto T. Motor neuron disease in the Kii Peninsula, Japan. Proc Aust Assoc Neurol. 1968;5:335–9.
5. Yase Y, Yoshida S, Kihira T, Wakayama I, Komoto J. Kii ALS dementia. Neuropathology. 2002;21:105–109.
6. World Federation of Neurology Research Group on Motor Neuron Diseases: El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. A Consensus Conference held at Airlie House, Warrenton, Virginia April 2–4, 1998.
7. Murros K, Fogelholm R. Amyotrophic lateral sclerosis in middle-Finland: an epidemiological study. Acta Neurol Scand. 1983;67:41–7.
8. Mandrioli J, Faglioni P, Merelli E, Sola P. The epidemiology of ALS in Modena, Italy. Neurology. 2003;60:683–9.
9. Kondo K, Tsubaki T. Case-control studies of motor neuron disease: association with mechanical injuries. Arch Neurol. 1981;38:220–6.
10. Kondo K, Tsubaki T. Changing mortality patterns of motor neuron disease in Japan. J Neurol Sci. 1977;32:411–24.
11. Kondo K. Population dynamics of motor neuron disease. In: Tsubaki T, Yoyokura Y, eds. Amyotrophic Lateral Sclerosis. Baltimore: University Park Press; 1979. pp 61–1031.
12. Tashiro K, Okumura H, Morikawa F, Fujiki N, Hamada T, Yanagihara T, et al. The geographic distribution of ALS in Hokkaido Island multi-Institutes-collaborating study. In: Annual Report of the Research Committee of CNS Degenerative Diseases, The Ministry of Health and Welfare of Japan. 1990. pp 113–6.
13. Sorenson JE, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to1998. Neurology. 2002;59:280–2.
14. Chancellor AM, Warlow CP. Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J Neurol Neurosurg Psychiatry. 1992;55:1106–15.
15. Plato CC, Garruto RM, Galasko D, Craig U-K, Plato M, Gamst A, et al. Amyotrophic lateral sclerosis and Parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am J Epidemiol. 2003;157:149–57.
16. Kuzuhara S, Kokubo Y, Sasaki R, Narita Y, Yabana T, Hasegawa M, Iwatsubo T. Familial amyotrophic lateral sclerosis and Parkinsonism-dementia complex of the Kii peninsula of Japan: clinical and neuropathological study and tau analysis. Ann Neurol. 2001;49:501–11.
17. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995–1997. A population-based study. Neurology. 1999;52:504–9.

18. Uebayashi U, Yase Y, Tanaka H, Shimada Y, Toyokura Y. Prognosis of motor neuron disease in Japan. Neuroepidemiology. 1983;2:243–56.
19. Hudson AJ, Davenport A, Hader WJ. The incidence of amyotrophic lateral scleraosis in southwestern Ontario, Canada. Neurology. 1986;36:1524–8.
20. Riggs JE. Longitudinal Gompertzian analysis of amyotrophic lateral sclerosis mortality in the USA, 1977–1986: evidence for an inherently susceptible population subset. Mech Ageing Dev. 1990;55:207–20.

21. Kihira T, Yoshida S, Mitani K, Yasui M, Yase Y. ALS in the Kii Peninsula of Japan, with special reference to neuro-fibrillary tangles and aluminum. Neuropathology. 1993; 13:125–36.
22. Norris F, Shepherd R, Denys E, UK, Mukai E, Elias L, Holden D, Norris H. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci. 1993;118:48–55.
23. Kahana E, Zilber N. Changes in the incidence of amyotrophic lateral sclerosis in Israel. Arch Neurol. 1984;41:157–60.

特定疾患治療研究事業医療受給者の経年変化

受給者調査リンケージデータを用いた解析

シバサキ　トモ ミ　　　ナガ イ　マサ キ　　　フチガミ　ヒロ シ　　ニシナ　モト コ
柴﨑　智美*　永井　正規*　渕上　博司2*　仁科　基子*

オオ タ　アキ コ　　カワムラ　タカシ　　オオ ノ　ヨシユキ
太田　晶子*　川村　　孝3*　大野　良之4*

目的　過去に実施された 4 回の医療受給者全国調査で入手された情報をリンケージし，最長13年間における受給継続状況を，疾患別，性年齢別，医療保険の種類別，都道府県別に明らかにする。また性別・疾患別の受給継続率を推計し，特定疾患治療研究事業対象者の医療受給者証交付継続状況を明らかにする。

方法　1992年度給付対象であった34疾患の受給者について，過去 4 回（1984年度，88年度，92年度，97年度）実施した医療受給者全国調査の各年度のデータを，疾患毎に①性，生年月日と居住地都道府県が一致した場合に同一者とみなす②受給者番号と居住地市町村が年度間で一致した場合は，性，生年月日の年号，年，月と日の 5 つのなかで 4 つが一致すれば同一者とみなすとする方法で個人単位のリンケージを行った。各調査年度に観察された受給者がそれ以降に実施された全国調査の時点でも受給しているか否かで継続状況を区分した。この区分方法で，疾患毎に各年度の受給者のその後 4 （または 5），8 （または 9），13年間の継続率を算出した。さらに，受給継続率の推計値を単年毎に算出し，84, 88, 92年度受給者から得られた単年毎の継続率を平均した平均受給継続率も算出した。

結果　受給者全体では，約70％が 4 年，約55％が 8～9 年受給を継続し，25～30％程度が受給を 4 年以内に中止している。疾患別には，全身性エリテマトーデスやベーチェット病などのいわゆる自己免疫疾患で長期に受給を継続する者の割合が高く，劇症肝炎，アミロイドーシス，筋萎縮性側索硬化症など生命予後の比較的不良な疾患で継続する割合が低い。また男より女の方が長期継続者の割合が高い。

受給継続率は，受給者全体よりも各調査年度の新規受給者で低く，給付対象となった年度が古い疾患では，男の受給継続率が女よりも低くなっているが，最近給付対象となった疾患では男の方が女よりも高い傾向がある。

結論　過去 4 回の医療受給者調査のリンケージデータを利用することによって，性・年齢別，都道府県別，疾患別，保険の種類別に特定疾患医療受給者の受給継続状況，最長13年後までの受給継続率の特徴を明らかにすることができた。特定疾患に関する医療制度を始めとする医療・保険制度の改革が行われていく中で，これらの社会的な要因によって受給継続状況は変化することが予測され，今後も注意深い観察が必要である。

Key words：特定疾患治療研究事業，医療受給者，全国調査，リンケージデータ

* 埼玉医科大学公衆衛生学
2* 埼玉県健康づくり事業団
3* 京都大学・保健管理センター
4* 独立行政法人・労働者健康福祉機構旭労災病院
　〒350-0495 埼玉県入間郡毛呂山町毛呂本郷38
　埼玉医科大学公衆衛生学教室　柴﨑智美

I　目　　　的

特定疾患治療研究事業は，対象疾患（2004年 4 月現在45疾患）に罹患した患者が申請により医療費の自己負担分を公費で補助している。厚生省特定疾患難病の疫学調査研究班（現特定疾患の疫学に関する研究班）では，1984年度（昭和59年